Skip to main content
Premium Trial:

Request an Annual Quote

OpGen Provides Additional Info to FDA on Antimicrobial Resistance Gene Panel

NEW YORK – OpGen announced Tuesday it has issued a formal response to the US Food and Drug Administration's request for additional information for its Acuitas AMR Gene Panel premarket submission.

OpGen originally submitted 510(k) premarket notification for the test in May 2019, and the FDA has requested additional information twice: once in July 2019, and once at the beginning of 2020. OpGen's response to the 2020 request was delayed in June due to the COVID-19 pandemic. The PCR-based test detects 47 antibiotic resistance genes in less than three hours from bacterial isolates.

The company said in a statement it has been working with the FDA's review team to address the outstanding questions and open items. OpGen COO Johannes Bacher added the firm is waiting on final feedback from FDA and "a swift FDA clearance decision in the coming weeks."

The Acuitas AMR Gene Panel is currently being used for testing isolates in a collaboration project with the New York State Department of Health. In June, the partnership was expanded after first-year milestones were reached. 

The Scan

Tara Pacific Expedition Project Team Finds High Diversity Within Coral Reef Microbiome

In papers appearing in Nature Communications and elsewhere, the team reports on findings from the two-year excursion examining coral reefs.

Study Examines Relationship Between Cellular Metabolism, DNA Damage Repair

A new study in Molecular Systems Biology finds that an antioxidant enzyme shifts from mitochondria to the nucleus as part of the DNA damage response.

Stem Cell Systems Target Metastatic Melanoma in Mouse Model

Researchers in Science Translational Medicine describe a pair of stem cell systems aimed at boosting immune responses against metastatic melanoma in the brain.

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.